Russia plans to speed registration of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), an expensive drug from the USA’s Vertex Pharmaceuticals (Nasdaq: VRTX), which is indicated for the treatment of cystic fibrosis.
So far, representatives of patient community have already called on the Russian Ministry of Health to speed registration of the drug.
According to them, procurements of the drug should be carried out as part 14 VZN federal program (which regulates procurements of the most expensive drug for state needs).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze